Premier Alternatives

Genomenon

Ann Arbor, MI · Founded 2014 · Privately Held (backing)

Developer of genome interpretation software designed to improve cancer diagnosis and treatment. Genomenon is based in Ann Arbor, MI and was founded in 2014. Its last known valuation is $68 million. It has raised $36.8 million across 4 recorded rounds; the latest was a $5.5 million early-stage round in May 2024.

Last price · $/share
—
Implied valuation
$68.0M
Total raised
$36.8M
Last round
Early Stage VC
May 2024

Genomenon key facts

  • Developer of genome interpretation software designed to improve cancer diagnosis and treatment.
  • Genomenon’s last known valuation is $68.0M.
  • It has raised $36.8M across 4 recorded rounds; the latest was Early Stage VC ($5.5M) in May 2024.
  • Notable investors include Michigan Rise, Invest Detroit Ventures, Innovation Partnerships, Beringea, Spring Mountain Capital — 25 tracked in total.
  • Genomenon has filed 4 Form Ds with the SEC since 2015, most recently May 2024 ($5.5M sold to 30 investors).
  • Status: Privately Held (backing).
Free account
More of Genomenon with a free account
  • ·The complete investor list: 25 names
  • ·Watch Genomenon: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Genomenon funding rounds

4 rounds
May 2024Early Stage VC$5.5MSEC filing▮
Feb 2022Early Stage VC$20.0MSEC filing▮
May 2020Seed Round$2.9MSEC filing▮
Aug 2015Seed Round$446KSEC filing▮
Full funding history →

Genomenon valuation

Genomenon's last known valuation is $68 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Genomenon raised?

Genomenon has raised $36.8 million across 4 recorded rounds since 2015. The largest was a $5.5 million early-stage round in May 2024.

Genomenon has filed 4 Form Ds with the SEC since 2015, most recently in May 2024 ($5.5 million sold to 30 investors).

Genomenon investors

25 investors are on record for Genomenon, including Michigan Rise, Invest Detroit Ventures, Innovation Partnerships and Beringea. By type, the record holds 4 venture capital firms and 1 growth equity firm. The early-stage round in May 2024 drew 30 investors.

About Genomenon

Developer of genome interpretation software designed to improve cancer diagnosis and treatment. The company's software offers a set of diagnostic and discovery tools to identify disease-causing genomic variants and assists in treating cancer and other heritable diseases, enabling physicians to improve patient outcomes.

Sector
Healthcare
HQ
Ann Arbor, MI, United States
Founded
2014
Employees
150
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$68.0M

Genomenon’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.